Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A carries a market capitalization of 30.88B, placing it among publicly traded companies globally. Its enterprise value stands at 29.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A has 264.71M shares outstanding.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 58.71. The price-to-sales ratio is 18.94, and the price-to-book ratio stands at 17.95.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A trades at an EV/EBITDA multiple of 56.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 17.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 56.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 29.22B versus a market cap of 30.88B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A maintains a current ratio of 2.50, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.25, indicating elevated leverage, while an interest coverage ratio of 20.87 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A posted a return on equity (ROE) of 35.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 16.32, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.60M in revenue per employee across its workforce of 1,018.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.58 indicates how many times Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A recorded an income tax benefit of -3.01M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 521.21M, leaving 525.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A's stock has declined approximately 4.14% over the past 52 weeks. The 50-day moving average sits at 112.80, while the 200-day moving average is 103.96.

Over the twelve months ended June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A generated 1.63B in revenue and converted that into 525.94M in net income, yielding earnings per share of 1.98. EBITDA reached 520.70M, while operating income came in at 516.19M.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A holds 2.47B in cash and equivalents against 812.94M in total debt, resulting in a net debt position of -1.34B. Total book value stands at 1.72B, with working capital of 1.78B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A posted a gross margin of 93.58, reflecting its pricing power and cost economics. The operating margin of 31.66 and net profit margin of 32.26 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A paid dividends of 0.09 per share. The dividend payout ratio of 4.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A shareholders.

As of June 30, 2026, Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A has an Altman Z-Score of 11.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.